CD16+ monocytes in breast cancer patients: expanded by monocyte chemoattractant protein-1 and may be useful for early diagnosis

Feng, Alei; Zhu, Jian; Sun, Jia; Yang, Meng; Neckenig, Markus; Wang, Xiu Wen; Shao, Qianqian; Song, Bingfeng; Yang, Qifeng; Kong, Beihua; Qu, Xiujuan

doi:10.1111/j.1365-2249.2011.04321.x

Cited by 59 publications

(61 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…4a for gating strategies in these myeloid cell populations in the primary tumor). As is seen in human breast cancer patients 32,33 , neutrophils and Ly6C hi monocytes were markedly expanded in tumor bearing m ice and also expressed TSLP. In contrast, these populations in tumor-free mice did not (Supplementary Fig.…”

Section: Resultssupporting

confidence: 64%

A tumor–myeloid cell axis, mediated via the cytokines IL-1α and TSLP, promotes the progression of breast cancer

Kuan¹,

Ziegler

2018

Nat Immunol

100

View full text Add to dashboard Cite

Tumors actively manipulate the immune response through the production of factors that attract immune cells and subsequently alter their ability to recognize and effectively remove the tumor. While this immune evasion mechanism is an important aspect of tumor survival, the factors that serve as primary growth factors for the tumor are less understood. Here, we demonstrated a novel mechanism by which breast cancer cells manipulate tumor-infiltrating myeloid cells to maintain their survival. Tumor-derived interleukin 1α (IL-1α), acting on infiltrating myeloid cells, induced the expression of a critical tumor survival factor, the cytokine thymic stromal lymphopoietin (TSLP). TSLP promoted the survival of the tumor cells through induction of Bcl-2 expression. TSLP signaling was also required for metastasis to the lung. These studies define a novel IL-1α–TSLP-mediated crosstalk between tumor-infiltrating myeloid cells and tumor cells in the control of metastatic breast cancer.

show abstract

Section: Resultssupporting

confidence: 64%

A tumor–myeloid cell axis, mediated via the cytokines IL-1α and TSLP, promotes the progression of breast cancer

Kuan¹,

Ziegler

2018

Nat Immunol

100

View full text Add to dashboard Cite

show abstract

“…CD14 high CD16 + monocytes have been shown to expand in various inflammatory conditions, including sepsis, asthma, breast cancer and chronic hepatitis B (HBV) infection [26], [27], [28]. There is some debate on whether these monocytes are considered pro-inflammatory or anti-inflammatory since in the majority of clinical reports, CD16+ monocytes have been analyzed and catalogued as one single subset.…”

Section: Discussionmentioning

confidence: 99%

Transforming Growth Factor-β, Macrophage Colony-Stimulating Factor and C-Reactive Protein Levels Correlate with CD14highCD16+ Monocyte Induction and Activation in Trauma Patients

et al. 2012

View full text Add to dashboard Cite

Severe injury remains a leading cause of death and morbidity in patients under 40, with the number of annual trauma-related deaths approaching 160,000 in the United States. Patients who survive the initial trauma and post-traumatic resuscitation are at risk for immune dysregulation, which contributes to late mortality and accounts for approximately 20% of deaths after traumatic injury. This post-traumatic immunosuppressed state has been attributed to over-expression of anti-inflammatory mediators in an effort to restore host homeostasis. We measured a panel of monocyte markers and cytokines in 50 severely injured trauma patients for 3 days following admission. We made the novel observation that the subpopulation of monocytes expressing high levels of CD14 and CD16 was expanded in the majority of patients. These cells also expressed CD163 consistent with differentiation into alternatively activated macrophages with potential regulatory or wound-healing activity. We examined factors in trauma plasma that may contribute to the generation and activation of these cells. The percentage of CD14highCD16+ monocytes after trauma correlated strongly with plasma C-reactive protein (CRP) transforming growth factor-β (TGF-β), and macrophage colony-stimulating factor (M-CSF) levels. We demonstrate a role for TGF-β and M-CSF, but not CRP in generating these cells using monocytes from healthy volunteers incubated with plasma from trauma patients. CD16 is a receptor for CRP and IgG, and we showed that monocytes differentiated to the CD14highCD16+ phenotype produced anti-inflammatory cytokines in response to acute phase concentrations of CRP. The role of these cells in immunosuppression following trauma is an area of ongoing investigation.

show abstract

“…Despite phenotypic similarity associated with the expression of CD16 receptor both aforementioned populations are characterized by different biological activities [10]. Increased fraction of CD14+CD16+ subpopulation amongst peripheral blood monocytes was observed in the course of infections and inflammatory processes [11,12], in septic states [13], and in some malignancies [14,15]. The CD14+CD16+ cells are defined as nonclassical [7] monocytes since compared to classical monocytes, they synthesize and release relatively higher amounts of tumor necrosis factor α (TNF-α) when stimulated with LPS, and do not secrete interleukin 10 (IL-10) or release only small amounts of this cytokine [16].…”

Section: Introductionmentioning

confidence: 99%

“…Little is known about the phenotype of peripheral blood monocytes in patients with gastric malignancies. Moreover, previous observation of increasing the percentage of CD14+CD16+ monocytes in some malignancies [14,15] were made based on the division of monocytes on CD14+CD16-and CD14+CD16+. Therefore, the aim of the present study was to determine the phenotype of peripheral blood monocytes in the gastric cancer patients in relation to the currently used classification of monocytes subpopulation described above.…”

Section: Introductionmentioning

confidence: 99%

Clinical immunology Gastric cancer increase the percentage of intermediate (CD14++CD16+) and nonclassical (CD14+CD16+) monocytes

Eljaszewicz¹,

Jankowski²,

Gackowska³

et al. 2012

cejoi

View full text Add to dashboard Cite

CD16+ monocytes in breast cancer patients: expanded by monocyte chemoattractant protein-1 and may be useful for early diagnosis

Abstract: Summary

Cited by 59 publications

References 39 publications

A tumor–myeloid cell axis, mediated via the cytokines IL-1α and TSLP, promotes the progression of breast cancer

A tumor–myeloid cell axis, mediated via the cytokines IL-1α and TSLP, promotes the progression of breast cancer

Transforming Growth Factor-β, Macrophage Colony-Stimulating Factor and C-Reactive Protein Levels Correlate with CD14highCD16+ Monocyte Induction and Activation in Trauma Patients

Clinical immunology Gastric cancer increase the percentage of intermediate (CD14++CD16+) and nonclassical (CD14+CD16+) monocytes

Contact Info

Product

Resources

About